Aldeyra Therapeutics (ALDX) vs LeonaBio (LONA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
LeonaBio (LONA) has outperformed Aldeyra Therapeutics (ALDX) over the past year, gaining 46.7% versus a loss of 83.8%. Over five years, ALDX leads with a -89.0% price change compared with -94.0% for LONA. Aldeyra Therapeutics is the larger company by market cap ($55.3 million vs $54.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALDX | LONA |
|---|---|---|
| Share price | $0.9163 | $5.75 |
| Market cap | $55.28M | $54.17M |
| 1-day change | -3.31% | 0.00% |
| YTD return | -82.31% | -24.04% |
| 1-year return | -83.84% | +46.68% |
| 5-year return | -89.01% | -93.99% |
| EPS (TTM) | $-0.38 | $-23.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.93 | $14.21 |
| 52-week low | $0.862 | $2.21 |
| Distance from 52-week high | -84.55% | -59.54% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +620.29% | +201.39% |
| Average volume | 1.18M | 185.45K |
| Shares outstanding | 60.33M | 9.42M |
| Employees | 6 | 19 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LONA has outperformed ALDX by 130.5 percentage points over the past year.
About Aldeyra Therapeutics
ALDX stock →Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About LeonaBio
LONA stock →LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees
ALDX vs LONA FAQ
Which is bigger, Aldeyra Therapeutics or LeonaBio?
Aldeyra Therapeutics (ALDX) is larger, with a market capitalization of $55.28M compared with $54.17M for LeonaBio (LONA).
Which stock has performed better over the past year, ALDX or LONA?
LONA returned +46.68% over the past 12 months, compared with -83.84% for ALDX (price return, excluding dividends). Past performance does not predict future results.
Are Aldeyra Therapeutics and LeonaBio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Aldeyra Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for LeonaBio.